1. Clinical & Scientific Overview
Adrenaline (Epinephrine) Tartrate IP (TIP-MED-000451, Reference Code [SUPP-1]) is classified under
Supplementary Emergency Resuscitation & Anaphylaxis Module (Edition 2.7 Appendix B) as a Non-Selective Alpha-1, Alpha-2, Beta-1 & Beta-2 Adrenergic Receptor Agonist (Endogenous Catecholamine).
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug • NLEM 2022 Core Emergency Medicine • ISMP High-Alert.
Hospital & critical-care generic reference; verify institutional protocol and CDSCO package insert.
Standard hospital formulary strengths
3. Mechanism of Action & Pharmacodynamics
Targeted critical-care pharmacological mechanism.
4. Therapeutic Indications & Evidence-Supported Uses
- Hospital critical care and specialist management per clinical protocol.
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Specialist hospital dosing only; verify renal/hepatic function and institutional protocol.
Administration & Meal Timing: Administer under qualified healthcare supervision.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Hospital pharmacokinetic profile; monitor therapeutic response and organ clearance.
Hepatic and/or extrahepatic clearance.
Evaluate eGFR/CrCl before and during therapy.
Evaluate hepatic transaminases and bilirubin.
7. Contraindications, Precautions & High-Risk Warnings
- Known hypersensitivity to active ingredient or formulation excipients.
Key Clinical Precautions: High-alert hospital specialist agent; administer under close physiological and laboratory monitoring.
8. Adverse Effects Profile
- Refer to institutional monograph and package insert.
- Monitor for hemodynamic instability, organ toxicity, or severe hypersensitivity.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Verify co-administered critical-care medications for pharmacokinetic/pharmacodynamic interactions.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Continuous clinical, hemodynamic, and organ-function laboratory monitoring.
Pharmacist Patient Counselling Points:
- Explain treatment purpose, monitoring schedule, and warning symptoms to patient/caregiver.
Storage, Stability & Dispensing Safeguards: Store per official IP 2022 / manufacturer label instructions.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO • NCBI Bookshelf
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
/medicine/12-32-cmp175-adrenaline-epinephrine-tartrate-ip-supplementary-eme/ for complementary therapeutic comparison and dosing context.